Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › emphysema

Emphysema

Part of Chronic Obstructive Pulmonary Disease

Subtypes of Emphysema

Severe Lung Emphysema 1

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for emphysema

32 trials tracked for emphysema: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 505 citations.

32Trials tracked
9Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 8 Phase 3 1 Phase 2 6 Other / NA 17
  1. Phase 4 Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. Completed · 505 cited
  2. Phase 4 Hypoxic Pulmonary Vasoconstriction Pilot Study Completed · 114 cited
  3. Phase 4 Losartan Effects on Emphysema Progression Completed · 26 cited
  4. Phase 4 Efficacy of Losartan in Preventing Progression of COPD Completed
  5. Phase 4 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis Completed
  6. Phase 4 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Completed
Show 26 more trials
  1. Phase 4 Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency Completed
  2. Phase 4 Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) Completed
  3. Phase 3 Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease Completed
  4. Phase 2 Anti-Platelets in Chronic Obstructive Pulmonary Disease Completed
  5. Phase 2 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Completed
  6. Phase 2 Sildenafil for Chronic Obstructive Pulmonary Disease Completed
  7. Phase 2 Prostaglandin Inhibition for Emphysema Completed
  8. Phase 2 Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies Completed
  9. Phase 2 Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency Completed
  10. N/A Doxycycline for COPD in HIV-Infected Patients Completed
  11. N/A Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema Completed
  12. N/A Regulation of the Release of Inflammatory Mediators From Lung Macrophages. Completed
  13. N/A Advancing Symptom Alleviation With Palliative Treatment Completed
  14. N/A A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) Completed
  15. N/A Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  16. N/A Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability Completed
  17. N/A Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD) Completed
  18. N/A Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations Completed
  19. N/A Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy Completed
  20. N/A Home Pulmonary Rehabilitation for COPD Completed
  21. N/A Alpha-1 Carrier Genomics Study Completed
  22. N/A Leukocyte Function in Asthma and COPD Completed
  23. N/A Macrophage Phagocytosis in COPD Completed
  24. N/A The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD Completed
  25. N/A Implementing and Evaluating the Genie Tool in COPD Completed
  26. N/A Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Emphysema: what the trials found

Alpha1-proteinase inhibitor demonstrated a statistically significant reduction in the annual rate of change in lung density (p=0.029) 8. However, other trials evaluating Alpha1-proteinase inhibitor did not find statistically significant changes in the rate of change or absolute change in adjusted lung density 2.

Sildenafil administration was associated with a significant increase in perfused blood volume assessed for lung inflammation (p<0.05) 3.

Arformoterol tartrate inhalation solution showed no statistically significant difference in FEV1 at the 24-hour trough (p=0.073) or peak change over 12 hours (p=0.060) 9. Clinical data also indicate that Arformoterol tartrate is associated with specific rates of adverse events and usage patterns for rescue medications like Ipratropium Bromide and Albuterol/Levalbuterol 10.

Losartan did not show statistically significant changes in mean pct950 (p=0.133), FEV1 percent predicted (pre- or post-bronchodilator) 4, or change in percent emphysema on CT scan (p=0.06) and FEV1 (L) 7.

Recent results — preliminary, needs further review

  • A Phase 2 trial using a placebo showed no significant changes in pulmonary microvascular blood volume (p=0.84; p=0.98) or oxygen saturation (p=0.75) 1.

For the clinician treating this condition

  • Alpha1-proteinase inhibitor shows statistically significant evidence for slowing the annual rate of change in lung density, though results across different trials are inconsistent regarding absolute changes [2, 8].
  • Sildenafil is associated with increased perfused blood volume related to lung inflammation 3.
  • Arformoterol tartrate inhalation solution demonstrates consistent usage patterns and specific adverse event profiles, but did not reach statistical significance for peak FEV1 improvements in the studied timeframe [9, 10].
  • Losartan did not demonstrate statistically significant improvements in FEV1 or emphysema percentage on CT scans in the evaluated trials [4, 7].

AI synthesis of 8 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Retrospective analysis shows machine learning improves CT-based airway and emphysema mapping
Radiology & Imaging
Retrospective analysis shows machine learning improves CT-based airway and emphysema mapping New AI Scan Detects Lung Damage More Accurately Than Old Tech
This retrospective analysis evaluates a new feature-based parametric response mapping (PRMD) method using machine learning on CT scans for C…
A new AI tool scans lungs more accurately than old methods, helping doctors spot COPD damage even when images are noisy.
medRxiv Apr 27, 2026
Non-powered stapler linked to fewer postoperative air leaks than powered stapler in severe emphysema LVRS
Pulmonology & Critical Care RCT
Non-powered stapler linked to fewer postoperative air leaks than powered stapler in severe emphysema LVRS Small study compares stapler types for lung surgery in severe emphysema patients
A single-blinded RCT of 19 patients with severe lung emphysema undergoing lung volume reduction surgery found the non-powered AEON Endostapl…
A non-powered surgical stapler cut the rate of air leaks after lung surgery for severe emphysema by nearly half compared to a powered staple…
Apr 5, 2026